U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07260292) titled 'KPs Supplement for Inflammation, Oxidative Stress and Lipid Abnormalities in CKD Patients.' on Nov. 22.
Brief Summary: In this study, we investigated the potential of kefir peptides as an adjunct therapy for chronic kidney disease (CKD) and clinical proteinuria. Patients with stage 3 or 4 CKD received KPs treatment over three months, during which we monitored renal profile markers (BUN, creatinine), proteinuria marker (urine protein-to-creatinine ratio), inflammatory markers (hs-CRP), and additional biochemical parameters.
Study Start Date: Aug. 01, 2023
Study Type: INTERVENTIONAL
Condition:
Patients With Chronic Kidney Disease S...